Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2020-08-31 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (58 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report title, regulatory references, or any other information to classify it as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal or non-informative content defaults to Regulatory Filings (RNS) as a fallback category.
2020-08-31 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal announcement from Glenmark Pharmaceuticals Limited dated August 14, 2020, addressed to stock exchanges (BSE and NSE). It details the outcome of a Board Meeting held on the same date. The key points include the appointment of an Additional Independent Director and the recommendation for the appointment of new Statutory Auditors to be approved at the upcoming Annual General Meeting (AGM). The document references SEBI regulations and circulars related to disclosure requirements. It does not contain financial statements or detailed financial performance data but rather announces board-level changes and auditor appointment recommendations. This fits the category of Board/Management Information (MANG), as it concerns changes in the company's board and auditor appointments, not the full audit report or annual report itself.
2020-08-14 English
Financial Result Updates
Regulatory Filings
2020-08-14 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the introduction of a higher strength (400 mg) version of the drug FabiFlu® by Glenmark Pharmaceuticals. It includes details about the new dosage, clinical trials, and the company's R&D efforts. There are no financial statements, regulatory filings, or detailed financial data. The document is a media release intended for public and investor information about a product update, not a financial report or regulatory filing. Therefore, it fits best under the category of a Capital/Financing Update (CAP) as it relates to a significant product development announcement by the company that could impact its market position and investor perception.
2020-08-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation letter for an earnings call scheduled on August 17, 2020, for Glenmark Pharmaceuticals' Q1 FY 2020-21 results. It includes dial-in numbers and contact details for clarifications. There is no actual financial data or detailed financial report included, only an announcement of the upcoming earnings call event. Therefore, this document is best classified as a Call Transcript (CT) category, specifically an invitation or announcement related to a conference call. However, since it is only an invitation and not the transcript itself, the closest fitting category is Call Transcript (CT) as it relates to the earnings call event. Confidence is high due to clear references to the earnings call date, time, and dial-in information.
2020-08-05 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for August 14, 2020, to consider and approve the unaudited financial results for the first quarter ended June 30, 2020. It references compliance with SEBI regulations and insider trading code, and informs about the trading window closure. The document is short (1934 characters) and serves as an announcement of a board meeting and upcoming financial results approval, not the financial results report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a general regulatory announcement about the board meeting and financial results approval.
2020-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.